Researchers found remission was far more likely after bariatric surgery than with intensive medical and lifestyle care over the long run.
Recap by typeshit. Full story at Medical Xpress.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
The once-daily obesity tablet came through an expedited review and can be taken without food rules. Lilly paired a cash price with a discount for many insured users.
MedPage Today
Among 339,092 MS patients, steroid-treated relapses ran 1.85% with GLP-1 use versus 4.84% without, a team from UC Riverside reported at MSToronto2026.
Loading…